Bret M Stephens
Overview
Explore the profile of Bret M Stephens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bahrambeigi V, Lee J, Branchi V, Rajapakshe K, Xu Z, Kui N, et al.
Cancer Res
. 2024 Mar;
84(10):1719-1732.
PMID: 38451249
Significance: The development of an approach to interrogate molecular subtypes, cancer-associated pathways, and differentially expressed genes through RNA sequencing of plasma extracellular vesicles lays the foundation for liquid biopsy-based longitudinal...
2.
Kolbinger F, Bernard V, Lee J, Stephens B, Branchi V, Raghav K, et al.
J Gastrointest Cancer
. 2023 Mar;
54(4):1276-1285.
PMID: 36862364
Purpose: Cancer of unknown primary (CUP) accounts for 2-5% of all cancer diagnoses, wherein standard investigations fail to reveal the original tumor site. Basket trials allocate targeted therapeutics based on...
3.
Monberg M, Geiger H, Lee J, Sharma R, Semaan A, Bernard V, et al.
Nat Commun
. 2022 Jun;
13(1):3652.
PMID: 35752636
Heterogeneity is a hallmark of cancer. The advent of single-cell technologies has helped uncover heterogeneity in a high-throughput manner in different cancers across varied contexts. Here we apply single-cell sequencing...
4.
Lee J, Bernard V, Semaan A, Monberg M, Huang J, Stephens B, et al.
Clin Cancer Res
. 2021 Aug;
27(21):5912-5921.
PMID: 34426439
Purpose: Precision medicine approaches in pancreatic ductal adenocarcinoma (PDAC) are imperative for improving disease outcomes. With molecular subtypes of PDAC gaining relevance in the context of therapeutic stratification, the ability...
5.
Semaan A, Bernard V, Kim D, Lee J, Huang J, Kamyabi N, et al.
Br J Cancer
. 2021 Mar;
124(12):1970-1977.
PMID: 33785875
Background: Limited accessibility of the tumour precludes longitudinal characterisation for therapy guidance in pancreatic ductal adenocarcinoma (PDAC). Methods: We utilised dielectrophoresis-field flow fractionation (DEP-FFF) to isolate circulating tumour cells (CTCs)...
6.
Semaan A, Bernard V, Lee J, Wong J, Huang J, Swartzlander D, et al.
Clin Cancer Res
. 2020 Nov;
27(4):1082-1093.
PMID: 33188144
Purpose: Most patients with pancreatic ductal adenocarcinoma (PDAC) present with surgically unresectable cancer. As a result, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the most common biospecimen source available for diagnosis...
7.
Bernard V, Semaan A, Huang J, San Lucas F, Mulu F, Stephens B, et al.
Clin Cancer Res
. 2018 Nov;
25(7):2194-2205.
PMID: 30385653
Purpose: Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive. Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms (IPMNs), represent a pathway to invasive neoplasia, although the molecular correlates...
8.
Bernard V, Kim D, San Lucas F, Castillo J, Allenson K, Mulu F, et al.
Gastroenterology
. 2018 Sep;
156(1):108-118.e4.
PMID: 30240661
Background & Aims: We aimed to investigate the clinical utility of circulating tumor cell DNA (ctDNA) and exosome DNA (exoDNA) in pancreatic cancer. Methods: We collected liquid biopsy samples from...